A randomized, cross-over, open-label study of the cost-effectiveness of NeoRecormon [epoetin beta] administered subcutaneously or intravenously in dialysis patients with renal anemia
Latest Information Update: 25 Feb 2010
At a glance
- Drugs Epoetin beta (Primary) ; Epoetin beta (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors Roche
- 27 Jun 2007 New trial record.